SecBot SecBot
8-K ·Filed Aug 14, 2026

RVP

RETRACTABLE TECHNOLOGIES INC
BEARISH
Impact 6/10
Horizonmonths Processed2mo ago SEC0001104659-26-097353
8-K context-dependent: Items 8.01
Actionable Insight ▼ Bearish

The core business is deteriorating with no catalyst for reversal — monitor for further cost-cutting measures or a potential liquidity event. The $6.4M equity gain is non-recurring, so next quarter's net income will likely swing back to a loss. Watch for any strategic alternatives or restructuring announcements given the $20M market cap and widening operating losses.

DirectionBearish
Confidencehigh
Horizonmonths
Latest settled — T+20d
RVP ▼ -2.86% at T+20d
SHORT call ✓ call won +2.86% · α vs SPY +0.88% · entry $0.7000 → $0.6800
Next anchor: T+60d in 13d
Latest observation: T+49 +19.47% FF3 residual α
Entry = T+0 close
Aug 14, 2026
via day close
T+1d
+2.86%
call -2.86% · α -3.53%
$0.7200
settled 2mo ago
T+5d
+4.29%
call -4.29% · α -5.48%
$0.7300
settled 2mo ago
T+20d
-2.86%
call +2.86% · α +0.88%
$0.6800
settled 6w ago
T+60d
Pending
in 13d

Price Chart

Loading chart...

Executive Summary

Retractable Technologies reported Q2 2026 net sales of $7.2M, down 30.8% YoY from $10.4M, with an operating loss of $5.1M (flat YoY). Net income of $2.8M was entirely driven by a $6.4M gain on sale of equity securities, masking an operating loss. H1 2026 net sales fell 23% to $14.4M from $18.7M, with operating losses widening to $11.3M from $9.8M. The revenue decline is broad-based across domestic and international segments, with no guidance provided to suggest a near-term recovery. The filing is bearish due to deteriorating core operating fundamentals, with the only positive being a one-time equity sale gain that is non-recurring.

Key Facts

  • Q2 2026 net sales $7.2M vs $10.4M YoY (-30.8%)
  • Q2 2026 operating loss $5.1M (flat YoY)
  • Q2 2026 net income $2.8M included $6.4M gain on sale of equity securities
  • H1 2026 net sales $14.4M vs $18.7M YoY (-23%)
  • H1 2026 operating loss $11.3M vs $9.8M YoY (widened)
  • Domestic unit sales decreased 35.1% in Q2, international revenues down 32.2%
  • Overall unit sales decreased 36.4% in Q2, 21% in H1
  • Tariff expenses $46K in Q2, $58K in H1 2026

Financial Impact

Revenue decline of $3.2M (30.8%) in Q2 and $4.3M (23%) in H1; operating loss widened by $1.5M in H1

revenueoperating incomeunit sales

Risk Factors

  • Continued revenue decline with no guidance for improvement
  • Non-recurring equity gain masks true operating losses; next quarter likely shows net loss
  • Tariff exposure remains a material cost risk despite mitigation efforts
  • Uncertainty around timing of future international orders

Market Snapshot

Exchange
NYSE
Sector
Surgical & Medical Instruments & Apparatus

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001104659-26-097353
Document: tm2623222d1_ex99.htm0001104659-26-097353
Document: 0001104659-26-097353-index-headers.html0001104659-26-097353
Document: 0001104659-26-097353-index.html0001104659-26-097353
Document: 0001104659-26-097353.txt0001104659-26-097353
4 reports for RVP
Performance horizon
Filters
Rows
Reports for RVP — sortable, filterable
TypeNow
Sep 30, 2026
27d ago
8-K
NEUTRAL ★ 2/10
$0.6900awaiting T+20—$0.5889 (−14.65%)
Aug 14, 2026
10w ago
8-K
BEARISH ★ 6/10
$0.7000 $0.6800▲ +2.86%▲ +0.88%$0.5889 (+15.87%)
Jun 30, 2026
17w ago
8-K
NEUTRAL ★ 2/10
$0.7200 $0.6702▼ −6.92%▼ −5.89%$0.5889 (−18.21%)
Mar 27, 2026
30w ago
DEFA14A
NEUTRAL ★ 2/10
$0.6700 $0.6400▼ −4.48%▼ −17.22%$0.5889 (−12.10%)
Showing 4 of 4

US Market Status

Market Closed — Opens Wed (16h 39m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 14, 2026